|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
89,554,000 |
Market
Cap: |
2.28(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$20.02 - $46.03 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Intellia Therapeutics is a genome editing company focused on developing therapeutics using CRISPR/Cas9 technology. CRISPR/Cas9, an acronym for Clustered, Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR associated 9 (Cas9), is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid (DNA). To realize the transformative potential of CRISPR/Cas9-based technologies, Co. is building a range of genome editing company, by utilizing its modular platform, to advance in vivo and ex vivo therapies for diseases with high unmet need.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
2,902 |
53,430 |
61,187 |
62,275 |
Total Sell Value |
$95,737 |
$1,583,155 |
$1,913,663 |
$1,961,404 |
Total People Sold |
2 |
7 |
8 |
8 |
Total Sell Transactions |
2 |
10 |
15 |
16 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Clark Eliana |
EVP, Chief Technical Officer |
|
2023-07-03 |
4 |
S |
$40.51 |
$14,584 |
D/D |
(360) |
45,146 |
|
30% |
|
Clark Eliana |
EVP, Chief Technical Officer |
|
2023-06-20 |
4 |
AS |
$45.00 |
$225,000 |
D/D |
(5,000) |
45,146 |
|
-43% |
|
Clark Eliana |
EVP, Chief Technical Officer |
|
2023-06-20 |
4 |
OE |
$12.27 |
$61,350 |
D/D |
5,000 |
50,146 |
|
- |
|
Bhanji Muna |
Director |
|
2023-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
4,425 |
14,393 |
|
- |
|
Chase William J |
Director |
|
2023-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
1,673 |
18,956 |
|
- |
|
Crowley John F |
Director |
|
2023-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
4,425 |
11,716 |
|
- |
|
Cohen Fred E |
Director |
|
2023-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
4,425 |
41,716 |
|
- |
|
Goodman Jesse |
Director |
|
2023-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
4,425 |
11,716 |
|
- |
|
Keresty Georgia |
Director |
|
2023-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
4,425 |
16,146 |
|
- |
|
Verwiel Frank |
Director |
|
2023-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
4,425 |
11,716 |
|
- |
|
Chase William J |
Director |
|
2023-04-14 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
6,800 |
|
1% |
|
Chase William J |
Director |
|
2023-04-14 |
4 |
A |
$0.00 |
$0 |
D/D |
10,483 |
17,283 |
|
- |
|
Basta James |
EVP, General Counsel |
|
2023-03-02 |
4 |
S |
$43.88 |
$47,741 |
D/D |
(1,088) |
55,279 |
|
-4% |
|
Basta James |
EVP, General Counsel |
|
2023-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
36,808 |
56,367 |
|
- |
|
Goddard Glenn |
EVP, Chief Financial Officer |
|
2023-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
27,484 |
42,888 |
|
- |
|
Sepp-Lorenzino Laura |
EVP, Chief Scientific Officer |
|
2023-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
29,938 |
47,567 |
|
- |
|
Leonard John M. |
President and CEO |
|
2023-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
91,036 |
857,861 |
|
- |
|
Hicks Derek |
EVP, Chief Business Officer |
|
2023-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
23,558 |
40,864 |
|
- |
|
Lebwohl David |
EVP, Chief Medical Officer |
|
2023-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
30,674 |
56,361 |
|
- |
|
Clark Eliana |
EVP, Chief Technical Officer |
|
2023-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
30,673 |
45,146 |
|
- |
|
Sepp-Lorenzino Laura |
EVP, Chief Scientific Officer |
|
2023-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,500 |
22,467 |
|
- |
|
Leonard John M. |
President and CEO |
|
2023-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,848 |
773,498 |
|
- |
|
Lebwohl David |
EVP, Chief Medical Officer |
|
2023-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,187 |
28,261 |
|
- |
|
Goddard Glenn |
EVP, Chief Financial Officer |
|
2023-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,062 |
17,831 |
|
- |
|
Bhanji Muna |
Director |
|
2022-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
2,014 |
9,968 |
|
- |
|
245 Records found
|
|
Page 2 of 10 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|